NLRP3 and colitis: WT161, an inhibitor of HDAC6, is confirmedto impede the activation of NLRP3 inflammasome by disrupting ASC spotformation and decreasing NLRP3 expression, mitigates intestinal damage,and suppresses intestinal inflammation in colitis models.